Our consortium partner Vactech Oy has released a new educational video introducing PRV-101, an investigational vaccine designed to prevent Coxsackie B virus infections. These infections are being studied as a possible trigger of type 1 diabetes.
The video presents the evidence linking these common enteroviruses to type 1 diabetes. It also explains how PRV-101 is intended to work.
PRV-101 contains inactivated Coxsackie B virus particles that cannot cause an infection. The vaccine is designed to help the immune system produce neutralising antibodies. These antibodies may block the viruses before they reach the pancreas and affect insulin-producing beta cells.
PRV-101 has completed a Phase 1 clinical trial, where it demonstrated a good safety profile. Vactech is now preparing for the next stage of clinical development.
One of ENT1DEP’s research goals is to investigate the immune responses induced by PRV-101. This work contributes to the project’s wider research into vaccines and other potential strategies for preventing enterovirus-associated type 1 diabetes.
“One of the ENT1DEP goals is to investigate immune responses induced by the multivalent CVB vaccine PRV-101, which has been developed by Vactech and tested in a recent Phase 1 clinical trial. As a pioneer in enterovirus vaccine development, Vactech contributes its deep expertise in vaccine R&D and translational science to the ENT1DEP project.” – Tero Välimaa, PhD, Chief Executive Officer, Vactech Oy
Watch the video below to learn more about PRV-101 and the science behind this preventive approach.
Video Link: The World’s First Preventive Vaccine for Type 1 Diabetes
You can also visit the ENT1DEP T1D Prevention page to learn more about enteroviruses, vaccine development and research into future strategies for preventing type 1 diabetes.
To learn more about type 1 diabetes prevention, vaccine development and related research, visit the website of our project partner, Vactech Oy.
Video produced by Vactech Oy. Originally published in the Vactech article, “Vactech releases a new video explaining the science behind PRV-101 vaccine”, on 13 April 2026.